Skip to main content
. Author manuscript; available in PMC: 2024 Aug 8.
Published in final edited form as: Oral Oncol. 2023 Sep 2;146:106562. doi: 10.1016/j.oraloncology.2023.106562

Figure 3. JAK2/STAT1 and FGF Pathway Inhibition Abrogates PD-L1 Expression in HNSCC Cell Lines.

Figure 3.

A, UM-SCC-49-V5-LacZ and -V5-FGF6 cells were pre-treated with JAK2 inhibitor Fedratinib (2 μM) or vehicle control (DMSO) for 6 hours, followed by addition of IFNγ (10 ng/mL) as indicated. Cells were harvested 72 hours after IFNγ treatment and PD-L1 and STAT1 expression were assessed by western blot. B, UM-SCC-49-V5-LacZ and -V5-FGF6 cells were pre-treated with FGFR1–3 inhibitor BGJ398 (3μM), FGFR1 inhibitor PD173074 (3μM) or vehicle control (DMSO) for 6 hours, followed by addition of IFNγ (10ng/mL) as indicated. Cells were harvested 72 hours after IFNγ treatment and total PD-L1 and STAT1 expression were assessed by western blot. C, UM-SCC-14a cells were pre-treated with BGJ398 (3μM), PD173074 (3μM) or vehicle control (DMSO) for 6 hours, followed by addition of IFNγ (10ng/mL) as indicated. Cells were harvested 72 hours after IFNγ treatment and total PD-L1 and STAT1 expression were assessed by western blot.